This is a working overview of WADA, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-09 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
[Mn(DMF)6](BPh4)2 [Fe(DMF)6](B(CN)4)2 [Co(DMF)6]I2 [Ni(DMF)6](BPh4)2 [Zn(DMF)6](BPh4)2 [Ru(DMF)6](O3SCF3)2 [Ru(DMF)6](O3SCF3)3 [Cd(DMF)6]B12H12 By contrast with DMF, homoleptic complexes with formamide and methylformamide are rare.
==== Due to use of medication ==== Urine tests can be falsely positive in those that are taking the medications: chlorpromazine, promethazine, phenothiazines, methadone, aspirin, carbamazepine and drugs that cause high urinary pH.
==== Symptomatic treatment ==== Medications used to treat the cognitive symptoms of AD rather than the underlying cause include: four acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine, and donepezil) and memantine, an NMDA receptor antagonist. The acetylcholinesterase inhibitors are intended for those with mild to severe AD, whereas memantine is intended for those with moderate or severe Alzheimer's disease. The benefit from their use is small. Reduction in the activity of the cholinergic neurons is a well-known feature of AD. Acetylcholinesterase inhibitors are employed to reduce the rate at which the body breaks down acetylcholine (ACh), thereby increasing the concentration of ACh in the brain and combating the loss of ACh caused by the death of cholinergic neurons. Evidence supports medical efficacy in mild to moderate AD, and somewhat in the advanced stage. This does not extend to delaying symptom onset. Memantine is a noncompetitive NMDA receptor antagonist first used as an anti-influenza agent. It acts on the glutamatergic system by blocking NMDA receptors and inhibiting their overstimulation by glutamate. Memantine has been reported to have a small benefit in the treatment of moderate to severe AD. The combination of memantine and donepezil has been reported to be "of statistically significant but clinically marginal effectiveness". An extract of Ginkgo biloba known as EGb 761 has been used for treating AD and other neuropsychiatric disorders. Its use is approved throughout Europe.
=== Viral-mediated delivery === The gene silencing effects of transfected, designed siRNA are generally transient, but this difficulty can be overcome through an RNAi approach. Delivering this siRNA from DNA templates can be done through several recombinant viral vectors based on retrovirus, adeno-associated virus, adenovirus, and lentivirus. As of primary research work in 2006, the latter virus was the most efficient for stable delivery of siRNA to target cells, as it could be used to transduce nondividing cells, as well as to directly target the nucleus. These specific viral vectors have been synthesized to effectively facilitate siRNA that is not viable for transfection into cells. In some cases synthetic viral vectors can integrate siRNA into the cell genome, which allows for stable expression of siRNA and long-term gene knockdown. This technique is advantageous because it is an in vivo method, and can be effective for difficult to transfect cells. However, problems arise because it can trigger antiviral responses in some cell types, leading to mutagenic and immunogenic effects. This method has been shown to have potential for use in gene silencing of the central nervous system genes, e.g., in the treatment of Huntington's disease.
Sources: en.wikipedia.org
==== APCI MS ==== The source for APCI is similar to ESI except that ions are formed by the interaction of the heated analyte solvent with a corona discharge needle set at a high electrical potential. Primary ions are formed immediately surrounding the needle, and these interact with the solvent to form secondary ions that ultimately ionize the sample. APCI is particularly useful for the analysis of nonpolar lipids such as triacylglycerols, sterols, and fatty acid esters.
The Paleolithic ( PAY-lee-oh-LITH-ik, PAL-ee-), or Old Stone Age, is a period in human prehistory distinguished by the original development of stone tools. It represents almost the entire period of human prehistoric technology, extending from the earliest known use of stone tools by hominins, c. 3.3 million years ago, to the end of the Pleistocene, c. 11,650 cal BP. The Paleolithic Age in Europe preceded the Mesolithic Age, although the date of the transition varies geographically by several thousand years. During the Paleolithic Age, hominins grouped together in small societies such as bands and subsisted by gathering plants, fishing, and hunting or scavenging wild animals. The Paleolithic Age is characterized by the use of knapped stone tools, although at the time humans also used wood and bone tools. Other organic commodities were adapted for use as tools, including leather and vegetable fibers; however, due to rapid decomposition, these have not survived to any great degree. About 50,000 years ago, a marked increase in the diversity of artifacts occurred. In Africa, bone artifacts and the first art appear in the archaeological record. The first evidence of human fishing is also noted, from artifacts in places such as Blombos Cave in South Africa. Archaeologists classify artifacts of the last 50,000 years into many different categories, such as projectile points, engraving tools, sharp knife blades, and drilling and piercing tools.
Innovations continued through the Middle Ages with the introduction of silk production (in Asia and later Europe), the horse collar, and horseshoes. Simple machines (such as the lever, the screw, and the pulley) were combined into more complicated tools, such as the wheelbarrow, windmills, and clocks. A system of universities developed and spread scientific ideas and practices, including Oxford and Cambridge. The Renaissance era produced many innovations, including the introduction of the movable type printing press to Europe, which facilitated the communication of knowledge. Technology became increasingly influenced by science, beginning a cycle of mutual advancement.
Before the establishment of the State of Israel in 1948, the Druze lived in the Galilee and Mount Carmel, either in exclusively Druze villages or in villages mixed with Christians, where they had coexisted for centuries. Historically, the relationship between the Druze and their Christian neighbors was better compared to their relationship with their Muslim neighbors in neighboring villages. According to historian Ilan Pappé, during the 1948 Arab–Israeli War, in villages partly inhabited by Druze, Christians were generally exempt from expulsion. According to Pappé, in 1948, Israeli military rulers gathered Christians in the centers of several villages in the Galilee region, planning to deport them. However, Druze village leaders intervened, insisting that all Christians remain in their homes. They utilized all their influence and resources to ensure that the Christian residents could stay. The Galilean village of Rameh, with a Christian majority, was not displaced because of its large Druze population. While the "divide and rule" policy succeeded with the Druze, who were promised immunity, weapons, and privileges, by the Zionist militias, the Palestinian Christian communities were less "cooperative". Israeli Druze and Muslims have comparable socio-economic standards when compared to their wealthier and more educated Israeli Christian counterparts.
In efforts to curtail recreational drug use, governments worldwide introduced several laws prohibiting the possession of almost all varieties of recreational drugs during the 20th century. The "war on drugs" promoted by the United States, however, is now facing increasing criticism. Evidence is insufficient to tell if behavioral interventions help prevent recreational drug use in children. One in four adolescents in the United States has used an illegal drug, and one in ten of those adolescents who need addiction treatment get some type of care. School-based programs are the most commonly used method for drug use education; however, the success rates of these intervention programs are highly dependent on the commitment of participants and are limited in general.
Sources: en.wikipedia.org
As he was not an expert in either chemistry or computer programming, he collaborated with Stanford chemist Carl Djerassi to help him with chemistry, and Edward Feigenbaum with programming, to automate the process of determining chemical structures from raw mass spectrometry data. Feigenbaum was an expert in programming languages and heuristics, and helped Lederberg design a system that replicated the way Djerassi solved structure elucidation problems. They devised a system called Dendritic Algorithm (Dendral) that was able to generate possible chemical structures corresponding to the mass spectrometry data as an output. Dendral then was still very inaccurate in assessing spectra of ketones, alcohols, and isomers of chemical compounds. Thus, Djerassi "taught" general rules to Dendral that could help eliminate most of the "chemically implausible" structures, and produce a set of structures that could now be analyzed by a "non-expert" user to determine the right structure. The new rules include more knowledge of mass spectrometry and general chemistry. He also expanded the system so it can incorporate to NMR spectroscopy data in addition to mass spectrometry data. The Dendral team recruited Bruce Buchanan to extend the Lisp program initially written by Georgia Sutherland. Buchanan had similar ideas to Feigenbaum and Lederberg, but his special interests were scientific discovery and hypothesis formation.
Cataracts: Extended usage of corticosteroids may cause clouding at the back of the lens, also known as posterior subcapsular cataract. This type of cataract reduces the path of light reaching the eye, which interferes with a person's reading vision. Consumption of prednisolone eye drops post-surgery may also retard the healing process. Corneal thinning: When corticosteroids are used in the long term, corneal and scleral thinning is also one of the consequences. When not ceased, thinning may ultimately lead to perforation of the cornea. Glaucoma: Prolonged use of corticosteroids has a chance of causing a raised intraocular pressure (IOP), injuring the optic nerve and weakening visual awareness. Corticosteroids should be used cautiously in patients with concomitant conditions of glaucoma. Doctors track patients' IOP if they are using corticosteroid eye drops for more than 103 days.
12 April – US President Joe Biden arrived in County Louth, one of his ancestral homelands, where crowds lined the streets in Carlingford and Dundalk. This followed a visit to Northern Ireland the previous day, as part of a four-day visit to the island of Ireland. 13 April – Biden visited President Michael D. Higgins at Áras an Uachtaráin and Taoiseach Leo Varadkar at Farmleigh House, before addressing a joint sitting of the Oireachtas at Leinster House, with the day ending with a banquet dinner at Dublin Castle. 14 April – Biden visited his ancestral homeland in County Mayo, visiting Knock Shrine and Mayo Roscommon Hospice, ending with a big event with around 27,000 in attendance featuring a public address and performances by The Coronas, The Chieftains and The Academic at St Muredach's Cathedral, Ballina. 17 April – Gerry Hutch was found not guilty of the 2016 murder of David Byrne at the Regency Hotel. 19 April – The 38th Cúirt International Festival of Literature opened in Galway. 22 April – It was announced that an investigator with the Garda Síochána Ombudsman Commission (GSOC) had attended a party celebrating the acquittal of Gerry Hutch the previous Monday, and that he was an associate of a relation of Hutch. The officer resigned when it became known, and GSOC intitiated an investigation. 23 April – An incorporeal Cabinet meeting agreed to send an Emergency Consular Assistance Team to Sudan, via Djibouti – some of them leaving on the night – on a mission to evacuate 150 Irish people and their families from the armed conflict there.
== Design constraints == The design of a molecular dynamics simulation should account for the available computational power. Simulation size (n = number of particles), timestep, and total time duration must be selected so that the calculation can finish within a reasonable time period. However, the simulations should be long enough to be relevant to the time scales of the natural processes being studied. To make statistically valid conclusions from the simulations, the time span simulated should match the kinetics of the natural process. Otherwise, it is analogous to making conclusions about how a human walks when only looking at less than one footstep. Most scientific publications about the dynamics of proteins and DNA use data from simulations spanning nanoseconds (10−9 s) to microseconds (10−6 s). To obtain these simulations, several CPU-days to CPU-years are needed. Parallel algorithms allow the load to be distributed among CPUs; an example is the spatial or force decomposition algorithm. During a classical MD simulation, the most CPU intensive task is the evaluation of the potential as a function of the particles' internal coordinates. Within that energy evaluation, the most expensive one is the non-bonded or non-covalent part. In big O notation, common molecular dynamics simulations scale by
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.